Have a feature idea you'd love to see implemented?
Let us know!
ESPR Esperion Therapeutics Inc
Price (delayed)
$1.935
Market cap
$379.69M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.84
Enterprise value
$747.02M
Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering medicines that will make
Highlights
Esperion Therapeutics's EPS has surged by 70% YoY and by 13% QoQ
The gross margin has grown by 22% YoY
The net income has soared by 56% YoY but it has contracted by 14% from the previous quarter
The equity has decreased by 17% QoQ but it has increased by 7% YoY
The quick ratio has contracted by 17% from the previous quarter and by 15% YoY
Esperion Therapeutics's debt has increased by 6% YoY
Key stats
What are the main financial stats of ESPR
Market
Valuations
Earnings
Shares outstanding
196.22M
Market cap
$379.69M
Enterprise value
$747.02M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.69
Revenue
$277.79M
EBIT
-$40.7M
EBITDA
-$40.66M
Free cash flow
-$9.91M
Per share
Balance sheet
Liquidity
EPS
-$0.84
Free cash flow per share
-$0.05
Book value per share
-$1.82
Revenue per share
$1.47
TBVPS
$1.87
Total assets
$352.32M
Total liabilities
$696.54M
Debt
$556.63M
Equity
-$344.22M
Working capital
$169.77M
Debt to equity
-1.62
Current ratio
1.97
Quick ratio
1.42
Net debt/EBITDA
-9.04
Margins
Efficiency
Dividend
EBITDA margin
-14.6%
Gross margin
81.8%
Net margin
-35.5%
Operating margin
1.8%
Return on assets
-34.2%
Return on equity
N/A
Return on invested capital
-7.8%
Return on capital employed
-23%
Return on sales
-14.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ESPR stock price
How has the Esperion Therapeutics stock price performed over time
Intraday
2.38%
1 week
-10.42%
1 month
11.21%
1 year
138.89%
YTD
-35.28%
QTD
17.27%
Financial performance
How have Esperion Therapeutics's revenue and profit performed over time
Revenue
$277.79M
Gross profit
$227.28M
Operating income
$4.95M
Net income
-$98.5M
Gross margin
81.8%
Net margin
-35.5%
The company's operating income has surged by 114% QoQ and by 103% YoY
ESPR's operating margin has surged by 112% since the previous quarter and by 101% year-on-year
Esperion Therapeutics's net margin has surged by 86% YoY and by 6% QoQ
The net income has soared by 56% YoY but it has contracted by 14% from the previous quarter
Growth
What is Esperion Therapeutics's growth rate over time
Valuation
What is Esperion Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
1.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.69
Esperion Therapeutics's EPS has surged by 70% YoY and by 13% QoQ
The equity has decreased by 17% QoQ but it has increased by 7% YoY
The price to sales (P/S) is 91% lower than the 5-year quarterly average of 13.5 and 29% lower than the last 4 quarters average of 1.8
ESPR's revenue is up by 21% since the previous quarter
Efficiency
How efficient is Esperion Therapeutics business performance
Esperion Therapeutics's return on sales has surged by 92% YoY but it has decreased by 21% QoQ
The return on invested capital has surged by 75% year-on-year but it has declined by 44% since the previous quarter
The return on assets has surged by 60% year-on-year but it has declined by 2.4% since the previous quarter
Dividends
What is ESPR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ESPR.
Financial health
How did Esperion Therapeutics financials performed over time
The total assets is 49% less than the total liabilities
The total assets has soared by 50% YoY but it has contracted by 6% from the previous quarter
The quick ratio has contracted by 17% from the previous quarter and by 15% YoY
The equity has decreased by 17% QoQ but it has increased by 7% YoY
ESPR's debt to equity is down by 15% year-on-year but it is up by 13% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.